|
|
(i)
|
(A)
|
patents,
patent applications, inventions, discoveries, machines, manufacturers,
compositions or matter, processes, formulae, designs, methods, techniques,
procedures, concepts, developments, technology, new and useful
improvements thereof and know-how relating thereto, whether or not
patented or patentable, specifically including the Patent Rights (as
hereinafter defined);
|
|
|
(ii)
|
all
registrations, applications, recordings and other legal protections or
rights related to any of the foregoing, and all rights to sue and recover
damages and obtain appropriate injunctive relief for past and future
infringement, dilution, misappropriation, violation or breach of such
rights; and
|
|
(iii)
|
all
improvements to any of the
foregoing.
|
|
|
|
|
(a)
|
United
States and foreign patents and patent applications listed in Schedule
1;
|
|
|
(b)
|
United
States and foreign patents issued from the applications listed in Schedule
1 and from divisionals and continuations of these
applications;
|
|
|
(c)
|
United
States continuation-in-part applications and foreign continuation-in-part
applications, and the resulting patents, based on the United States and
foreign applications listed in Schedule
1;
|
|
|
(a)
|
are
manufactured by using a process, or is otherwise covered by, in whole or
in part, the Intellectual Property
Rights;
|
|
|
(b)
|
are
derived, in whole or in part, from the Intellectual Property Rights;
or
|
|
|
(c)
|
are
sold, manufactured or used in any country under this
Agreement.
|
|
|
(a)
|
License
Territory. The license granted to PARI pursuant to this Section
3.1 extends worldwide. Notwithstanding the foregoing, both PARI
and ALRT acknowledge that the Patent Rights identified on Schedule 1
specifically cover the corresponding country(ies) noted
thereon.
|
|
|
(b)
|
Patent
Prosecution and Maintenance.
|
|
|
(i)
|
Patent
Rights in Protection Countries. During the term of this
Agreement ALRT shall take all steps necessary to apply for, seek issuance
of, and maintain during the term of this Agreement, Patent Rights for the
Products in the countries set forth in Schedule 2 attached hereto and
incorporated by reference herein (the “Protection
Countries”); provided, however, that ALRT shall not be required to
file for the Patent Rights in the
countries
|
|
|
listed
on Schedule 2 (except for the United States) until the
expiration of the Trial Period and PARI has not terminated this
Agreement prior to the end of the Trial Period. Prior to filing
for a Patent Right in a country listed on Schedule 2, PARI
and ALRT agree to review PARI’s commercialization plan for such country to
ensure PARI plans to commercialize. In the event PARI does not
yet have a commercialization plan for the Products in a country listed on
Schedule 2, no filing for a Patent Right will then be required in that
country. However, PARI may nevertheless request ALRT to file
for a Patent Right without a current commercialization plan, upon which
time PARI and ALRT shall split the costs of filing for a Patent Right in
that country until such time as PARI finalizes its commercialization plan
for that country and ALRT shall then cover all associated
costs. Such filing for a Patent Right will not need to take
place immediately, but must proceed in a manner and within a time period
to ensure rights are not lost based on priority of related US applications
(for example, filing at least a PCT patent application with the US
Receiving Office within one year of the filing of the US application and
subsequent filing of national applications within 30 months of the filing
of the US application). Following such filings for a Patent
Right, PARI shall be responsible for 50% of all maintenance fees related
to the Patent Rights in such other countries for the period from the
issuance of such Patent Rights in a country listed on Schedule 2 until the
commercial launch of the Products by, or on behalf of, PARI in such
country. The prosecution, filing and maintenance
of all Patent Rights for Products in the Protection Countries shall be the
primary responsibility of ALRT. ALRT shall keep PARI timely
advised with respect to the progress and status of such Patent Rights and
shall supply to PARI copies of all material correspondence and papers
received in connection therewith. ALRT shall take all steps to
provide such correspondence to and advise PARI in a timely manner in order
to permit PARI to comment on all actions before they are taken by patent
counsel. Any additional countries that PARI agrees with ALRT to
be included in Schedule 2 in accordance with (b)(ii) below, and the Patent
Rights therein, shall be governed by the terms and conditions of this
Agreement. All final decisions with respect to prosecution of
the Patent Rights shall be reasonably made by ALRT, taking into account
PARI’s comments. Notwithstanding anything to the contrary in
this Agreement, if PARI reasonably believes that ALRT may fail to make any
required payments or take any action required for the preparation, filing,
prosecution or maintenance of the Patent Rights within a reasonable time,
PARI shall provide ALRT with written notice of such
deficiency. If ALRT fails to take the required action within 30
days of the date of such notice, PARI shall have the right to thereafter
make any such required payments or take any such required action and ALRT
shall promptly reimburse PARI for any costs and expenses incurred with
respect to the foregoing.
|
|
|
(ii)
|
Additional
Countries. The parties may, by mutual written agreement, amend
Schedule 2 from time to time during the term of this Agreement to add
additional countries to the list of Protection Countries as (i) ALRT
applies for protection in such additional countries, and (ii) needed by
the parties for commercialization of Products. In the event
that PARI proposes that one or more countries be added to the list of
Protection Countries in Schedule 2 and ALRT fails or refuses to agree to
the addition of the country(ies) proposed by PARI within thirty (30) days
of its receipt of such proposal, then PARI shall have the right
to require ALRT to apply for, seek issuance of, and maintain Patent Rights
in such country(ies) at PARI’s expense, and ALRT shall promptly comply
with the foregoing. In all cases, the license and rights
granted to PARI hereunder shall include the rights to all such additional
country(ies).
|
|
|
(iii)
|
Expenses
of Patent Rights Prosecution. Subject to Section 3.1 (ii),
during the term of this Agreement ALRT shall pay all fees and costs
incurred by ALRT in connection with the Patent Rights, including, without
limitation, attorney fees relating to the filing, prosecution, and
maintenance of such Patent Rights. In addition to any other
rights or remedies that PARI may have, in the event that ALRT fails to pay
for the filing, prosecution or maintenance of such Patent Rights or any
portion thereof, or otherwise fails to prosecute the Patent Rights in the
United States or in any country included in the Protection Countries, PARI
shall have the right, but not the obligation, to do so, and ALRT shall
reimburse PARI for all costs and expenses incurred in connection
therewith.
|
|
|
(a)
|
Presentations. Upon
PARI’s request from time to time during the Term, a principal officer or a
knowledgeable employee of ALRT shall make himself/herself available to
make four (4) formal presentations per year concerning the Products, the
Intellectual Property Rights and any research findings related thereto at
no charge, provided that PARI shall pay all reasonable travel expenses
relating thereto that have been pre-approved by PARI prior to such
expenses being incurred. To the extent PARI desires ALRT to
make more than four presentations, ALRT shall do so on the same basis
provided that if ALRT does not have the staff available for such
presentations it may use qualified and knowledgeable consultants and its
reasonable out of pocket expenses, including the fees and expenses of such
consultants, each of which will require pre-approval from PARI in writing,
shall be reimbursed to ALRT by
PARI.
|
|
|
(b)
|
Scientific
Papers. ALRT and PARI shall work together concerning any
materials that are to be published that relate to the Products or the
Intellectual Property Rights.
|
|
|
(c)
|
Miscellaneous. Upon
PARI’s request, from time to time during the term of this Agreement, ALRT
shall assist PARI, at PARI’s expense, with any marketing, advertising, or
promotional matters that relate to the Products or the Intellectual
Property Rights.
|
|
|
(a)
|
With
respect to the Connectivity, the CHC Unit and the Software, ALRT shall
control all regulatory activities in accordance with this Section 3.10;
provided that ALRT shall (v) consult with PARI with respect to the
regulatory strategy related to any Product or any component thereof and
otherwise keep PARI reasonably involved in good faith discussions with
respect to such activities, (w) provide PARI with copies of correspondence
received from and to be provided to, regulatory authorities concerning any
Product or any component, (x) consider in good faith all reasonable
suggestions and comments provided by PARI with respect to such
correspondence and other communications with regulatory authorities, and
specifically, use best efforts to allow PARI reasonable advance
opportunity to comment on those portions of the initial submissions and
subsequent amendments with respect to the regulatory approvals related to
any Product or any component thereof, (y) use best efforts to respond to
all requests for information received from regulatory authorities with
respect to any Product or any component thereof in a timely and complete
manner, and (z) not voluntarily take any action or fail to take any action
which would be reasonably likely to have an adverse effect on the
development of any Product and related approvals. ALRT hereby
gives PARI the full right to access, use and
reference
|
|
|
(and
provide PARI with copies of) all regulatory applications and approvals
that ALRT obtains, directly or indirectly, with respect to the
Connectivity, the CHC Unit and the Software, including, but not limited
to, 510(k) approvals.
|
|
|
|
|
(b)
|
PARI
shall control all regulatory activities relating to its medical devices
and systems and shall own all regulatory approvals relating to the
forgoing.
|
|
|
(a)
|
Implementation. ALRT
agrees to provide personnel, its expertise and the professional, technical
and project management services as are necessary to manage the
administration and operation of the Software as used in connection with
Products, including offering a complete hosting environment for the
Software (from servers to backup technology). All Software
shall at all times comply with all applicable laws and regulations,
including, but not limited to HIPPA, COPPA and similar requirements. To
the extent PARI recommends any modifications to the Software as used in
connection with the CHC Unit and/or the Connectivity, ALRT shall use
commercially reasonable efforts to implement such recommended
modifications.
|
|
|
(b)
|
Product
Developments. ALRT shall from time to time provide PARI with such
up-to-date information concerning the Software as ALRT has available and
as PARI may from time to time reasonably
request.
|
|
|
(c)
|
Support
and Training. Upon request, ALRT shall make available to PARI (at such
time and place as agreed to by the parties) one or more suitably qualified
employees of ALRT for training PARI employees in matters relating to the
Software, including without limitation installation, support and operation
with Products. The duration, location, and other aspects of the training,
as well as the number of PARI employees to be trained, shall be determined
by mutual agreement.
|
|
|
(d)
|
Maintenance. ALRT
agrees to provide bug-fixes, patches and other updates with respect to the
Software for so long as a subscription for Monitoring activated through
the physicians and/or patients to whom PARI sells the CHC Unit via the
PARI Network endures and otherwise as PARI may from time to time
reasonably request. ALRT shall further correct any errors or
defects in the Software that cause it not to operate properly with the
Products, as well as any errors or defects in the documentation that
render such documentation inaccurate, erroneous or
unreliable.
|
|
(e)
|
Warranty.
ALRT shall warrant the operation of the Software, in its original
unaltered form, against system failures, error or bugs. This warranty
shall include, with respect to system failures, errors or bugs, ALRT using
its best efforts to promptly correct any such failures, errors or bugs, to
supply the correction in a timely fashion, and to answer all questions
that any physician, patient, any person in the PARI Network or PARI may
have regarding such failures, errors or
bugs.
|
|
|
(a)
|
if
the Monitoring services fee charged by ALRT (or its agent) is more than
$30
per month per patient (or the equivalent if the Monitoring services fee is
based on a different frequency), then, in the case of Option 1, the
Individual Subscription Amount shall be 16.67%
of the Monitoring services fee, and in the case of Option 2, the
Individual Subscription Amount shall be the sum of (i) 10%
of the Monitoring services fee plus (ii) $0.50
as long as no reimbursement code for the CHC Unit has been established by
a governmental agency; provided, however, that any
increase in the Monitoring services fee as a direct result solely of (x)
the increased cost of the outsourcing in case of Option 2 in excess
of $5.00
or (y) any add-ons to the Services, such as dial-up modems or other
disbursements or out-of-pocket expenses of ALRT requested and agreed to by
PARI or (y), shall not give right to an increase of the Individual
Subscription Amount; and
|
|
|
|
|
(b)
|
if the
Monitoring services fee charged by ALRT (or its agent) is less than $30
per patient per month (or equivalent if the Monitoring services
fee is based on a different frequency), then the Individual Subscription
Amount shall be as set forth in Section 4.2, unless otherwise agreed to by
the parties in writing.
|
|
|
(i)
|
number
of subscriptions for Monitoring activated through the physicians and/or
patients to whom PARI sells the CHC Units via the PARI
Network;
|
|
|
(ii)
|
total
billing for subscriptions for Monitoring activated through the physicians
and/or patients to whom PARI sells the CHC Units via the PARI Network;
and
|
|
|
(iii)
|
total
payment due.
|
|
|
(a)
|
ALRT
is duly authorized to enter into this Agreement and perform its
obligations hereunder and the performance of its obligations hereunder
does not conflict with or result in a breach of any other agreement to
which ALRT, its shareholders, directors or employees is a
party;
|
|
|
(b)
|
Schedule
1 sets forth a true, correct and complete list of (i) all of the
Intellectual Property Rights related to the Products that have been filed
with the United States Patent and Trademark Office, the United States
Copyright Office, or any other national or foreign agency administering
formal protection for proprietary rights, and (ii) all material
unregistered rights related to the Intellectual Property
Rights;
|
|
|
(c)
|
ALRT
exclusively owns the entire right, title, and interest in and to all of
the Intellectual Property Rights relating to the Products free and clear
from all encumbrances including, without limitation, the exclusive right
to use and license the same. ALRT further represents and
warrants that the Intellectual
Property
|
|
|
Rights
do not infringe or otherwise constitute an unauthorized use of the
proprietary rights of any third
party;
|
|
|
(d)
|
the
Intellectual Property Rights constitute all of the intellectual property
necessary to promote, make, have made, use, distribute and sell the
Products, on a worldwide basis;
|
|
(f)
|
no
third party has any right, title or interest in or to any of the
Intellectual Property Rights relating to the Products with the sole
exceptions of PGB Medical and
Aspen;
|
|
(g)
|
ALRT
has taken commercially reasonable measures to protect the secrecy,
confidentiality and value of the trade secrets and know-how included in
the Intellectual Property Rights. ALRT is not nor has it
received any notice that it is, in default (or with the giving of notice
or lapse of time or both, would be in default) under any license with
respect to the Intellectual Property
Rights;
|
|
(h)
|
neither
ALRT nor its Affiliates have never received any Claim alleging that ALRT’s
development or use of the Intellectual Property Rights interferes with,
infringes, or misappropriates any intellectual property rights of any
third party (including any claim that ALRT must license or refrain from
using any intellectual property rights of any third party in order to
exploit the Connectivity, CHC Unit and/or the
Software).
|
|
(i)
|
no
third party has interfered with, infringed upon, or misappropriated the
Intellectual Property Rights and there are no facts which would form a
reasonable basis for any claim of such interference, infringement, or
misappropriation;
|
|
(j)
|
no
claim is pending or, to the knowledge of ALRT, threatened which challenges
the legality, validity, enforceability, use, or ownership of any
Intellectual Property Rights, and there are no facts which would form a
reasonable basis for any such claim;
and
|
|
(k)
|
the
exploitation of the Products does not interfere with, infringe upon, or
misappropriate, any intellectual property rights of any third
party
|
|
|
(a)
|
PARI
agrees to be responsible for, and to defend, indemnify, and hold ALRT, and
any of its parents, successors, shareholders, officers, directors and
Affiliates, harmless against any and all claims, actions, suits,
liabilities, demands, expenses (including reasonable attorney fees and
disbursements), losses, costs, or damages (collectively, “Claims”)
actually incurred by ALRT, and any of its parents, successors,
shareholders, officers, directors or Affiliates, whether such Claim exists
directly between the parties hereto or relates to a third party, arising
out of or in connection with:
|
|
|
(i)
|
the
use of the Intellectual Property Rights in a manner that is inconsistent
with the terms and conditions of this
Agreement;
|
|
|
(ii)
|
any
breach of PARI’s obligations hereunder;
and
|
|
|
(iii)
|
any
breach by PARI of its representations and warranties set forth in Section
7.2.
|
|
|
(b)
|
ALRT
agrees to be responsible for, and to defend, indemnify, and hold PARI, and
any of its parents, successors, shareholders, officers, directors and
Affiliates harmless, against any and all Claims actually incurred by PARI,
and any of its parents, successors, shareholders, officers, directors or
Affiliates, whether such Claim exists directly between the parties hereto
or relates to a third party, arising out of or in connection
with:
|
|
|
(i)
|
the
use of the Intellectual Property Rights in a manner that is consistent
with the terms and conditions of this
Agreement;
|
|
(ii)
|
any
breach of ALRT’s obligations
hereunder;
|
|
(iii)
|
any
failure of or breach by ALRT of the representations and warranties set
forth in Section 7.1.;
|
|
(iv)
|
any
product liability claim relating to the Connectivity, CHC Unit or
Software; and
|
|
(v)
|
a
claim of infringement or misappropriation of the proprietary rights of any
third party by ALRT or its
Affiliates.
|
|
|
(a)
|
Termination
for Cause. If either PARI or ALRT is in breach of any of its
obligations under this Agreement and fails to remedy such breach within
thirty (30) days after receipt of written notice thereof from the other
party, the party not in breach shall have the option of terminating this
Agreement by giving written notice of termination in accordance with
Section 10.8.
|
|
|
(b)
|
Termination
of Agreement by PARI. PARI may terminate this Agreement for any
reason or no reason (i) at any time during the Trial Period by giving
written notice to ALRT, in which case this Agreement shall immediately
terminate, and (ii) following the Trial Period, upon not less than ninety
(90) days’ written notice to ALRT, in which case this Agreement shall
terminate on the 90th
day.
|
|
|
(a)
|
PARI’s
right to receive or recover and ALRT’s obligation to make payments accrued
as of the effective date of termination or as may become due and payable
after the effective date of termination as set forth in Article 4
above;
|
|
|
(b)
|
Each
party’s indemnification rights and obligations set forth in Article 7
above;
|
|
|
(c)
|
ALRT’s
obligation to maintain records hereunder as set forth in Section 4.3
above;
|
|
|
(d)
|
Each
party’s obligation to maintain insurance on behalf of the other party
hereto. Such obligation shall extend for so long as a
subscription for Monitoring activated through the physicians to whom PARI
sells the CHC Unit via the PARI Network
endures.
|
|
|
(e)
|
The
confidentiality obligation of both parties set forth in Article 9;
and
|
|
|
(a)
|
Either
party filing a voluntary petition for bankruptcy, reorganization, or an
arrangement under any bankruptcy or insolvency law, or an involuntary
petition under any such law being filed against a party hereto and not
dismissed within ninety (90) days;
and
|
|
|
(a)
|
was
in recipient’s rightful possession on a non-confidential basis prior to
receipt from the disclosing party;
|
|
|
(b)
|
is
or becomes, through no fault of the recipient, publicly
known;
|
|
|
(c)
|
is
furnished to the recipient by a third party without breach of a duty to
the disclosing party;
|
|
|
(d)
|
is
independently developed by the recipient without access to the disclosing
party’s Confidential Information;
or
|
|
|
(e)
|
such
disclosure is required by applicable law, provided that the recipient
shall apply for confidential treatment of this Agreement and/or the
proposed disclosure to the fullest extent permitted by law, shall provide
the disclosing party a copy of the confidential treatment request far
enough in advance of its filing, if reasonably practical, to give the
disclosing party a meaningful opportunity to comment thereon, and shall
use reasonable efforts to incorporate in such confidential treatment
request any reasonable comments of the disclosing
party.
|
|
|
(a)
|
Neither
ALRT nor PARI shall assign this Agreement or its rights and obligations
hereunder to a third party without the other party’s prior written
consent; and
|
|
|
(b)
|
Either
ALRT or PARI may assign this Agreement, without the other party’s consent,
to an Affiliate.
|
|
|
(b)
|
one
(1) business day following the date sent when sent by overnight delivery;
or
|
|
|
(c)
|
three
(3) business days following the date mailed when mailed by registered or
certified mail return receipt requested and postage prepaid to the
following address:
|
|
Country
|
Title
|
Serial
Number
|
Filing
Date
|
|
|
US
|
Medical
Reminder Device Suited for Use with Nebulizers
|
11/351,432
|
02/10/2006
|
|
|
Country
|
Title
|
Serial
Number
|
Filing
Date
|
|
|
US
|
Medical
Reminder Device Suited for Use with Nebulizers
|
11/351,432
|
02/10/2006
|
|
|
US
|
Patient
Care Coordination System Including Home Use of
|
Doc
09041
|
07/27/2009
|
|
|
Medical
Apparatus (Primarily the Software System, but
some
|
||||
|
Coverage
of connectivity may be possible)
|
||||
|
Country
|
Title
|
Serial
Number
|
Filing
Date
|
|
|
US
|
Patient
Care Coordination System Including Home Use of
|
Doc
09041
|
07/27/2009
|
|
|
Medical
Apparatus
|
||||
|
Product:
Constant Health Companion BOM
|
||||
|
Item
|
Usage
|
USDe
U/P with Scrap
|
USD
Amount
|
|
|
100
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
150
ohm (0805)
|
2
|
0.00107
|
0.00213
|
|
|
680
ohm (0805)
|
2
|
0.00107
|
0.00213
|
|
|
4K7
ohm (0805)
|
4
|
0.00107
|
0.00426
|
|
|
10K
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
15K
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
39K
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
56K
ohm (0805)
|
9
|
0.00107
|
0.00959
|
|
|
120K
ohm (0805)
|
2
|
0.00107
|
0.00213
|
|
|
270K
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
1.8M
ohm (0805)
|
1
|
0.00107
|
0.00107
|
|
|
CHIP
CAP 20P (0805)
|
1
|
0.00386
|
0.00386
|
|
|
CHIP
CAP 820P (0805)
|
2
|
0.00386
|
0.00773
|
|
|
CHIP
CAP 0.1uF (0805)
|
10
|
0.00386
|
0.03864
|
|
|
GOLD
CAP 0.33F
|
1
|
0.47969
|
0.47969
|
|
|
1N4148
|
11
|
0.00799
|
0.08794
|
|
|
CRYSTAL
32.768KHZ
|
1
|
0.04131
|
0.04131
|
|
|
TRAN.
2222A
|
1
|
0.01599
|
0.01599
|
|
|
TRAN.
3906
|
2
|
0.01332
|
0.02665
|
|
|
TRAN.
3904
|
2
|
0.01332
|
0.02665
|
|
|
BAR43FILM
|
5
|
0.04264
|
0.21320
|
|
|
BU4325F
|
1
|
0.09994
|
0.09994
|
|
|
74HC00N
|
1
|
0.09860
|
0.09860
|
|
|
EEPROM
24LC02
|
1
|
0.09194
|
0.09194
|
|
|
OKI
MCU MSM63188A-607 (DICE)
|
1
|
0.00000
|
0.00000
|
|
|
BSI
SRAM 32K X 8 (BS62LV256SC)
|
1
|
0.88343
|
0.88343
|
|
|
PCB
(OLD VERSION)
|
1
|
0.46903
|
0.46903
|
|
|
DB9
FEMALE CONNECTOR
|
1
|
0.17589
|
0.17589
|
|
|
BATTERY
INSULATION RING
|
1
|
0.00666
|
0.00666
|
|
|
T704
STN LCD
|
1
|
0.97137
|
0.97137
|
|
|
TACT
SWITCH
|
3
|
0.03065
|
0.09194
|
|
|
RESET
KEY
|
1
|
0.00933
|
0.00933
|
|
|
SLIDE
SWITCH
|
1
|
0.03864
|
0.03864
|
|
|
CR2032
LITHIUM BATTERY - "SONY"
|
1
|
0.17589
|
0.17589
|
|
|
ZEBRA
CONNECTOR
|
1
|
0.01865
|
0.01865
|
|
|
BUZZER
27 MM
|
1
|
0.03331
|
0.03331
|
|
|
TOP
CABINET (3 SILKSCREEN)
|
1
|
0.20387
|
0.20387
|
|
|
BOTTOM
CABINET
|
1
|
0.13724
|
0.13724
|
|
|
BATTERY
DOOR
|
1
|
0.03864
|
0.03864
|
|
|
SLIDE
SWITCH HOLDER
|
1
|
0.03864
|
0.03864
|
|
|
SMALL
KEY TOP (1 SILKSCREEN)
|
2
|
0.06796
|
0.13591
|
|
|
LARGE
KEY TOP (2 SILKSCREEN)
|
1
|
0.08661
|
0.08661
|
|
|
BACK
HOOK
|
1
|
0.03864
|
0.03864
|
|
|
BACK
BASE
|
1
|
0.06662
|
0.06662
|
|
|
COVER
FOR BACK BASE
|
1
|
0.03864
|
0.03864
|
|
|
LENS
|
1
|
0.15856
|
0.15856
|
|
|
BATTERY
PLATE +
|
1
|
0.01865
|
0.01865
|
|
|
BATTERY
PLATE -
|
1
|
0.01732
|
0.01732
|
||
|
WEIGHT
|
1
|
0.02132
|
0.02132
|
||
|
CUSHION
|
4
|
0.00666
|
0.02665
|
||
|
WIRE
|
2
|
0.00187
|
0.00373
|
||
|
M2
NUT
|
1
|
0.00613
|
0.00613
|
||
|
SCREW
2 X 5.0 PMT
|
1
|
0.00693
|
0.00693
|
||
|
SCREW
PA 1.7 x 5 mm
|
9
|
0.00133
|
0.01199
|
||
|
SCREW
PB 2 x 6 mm
|
4
|
0.00160
|
0.00640
|
||
|
SCREW
PB 2.3 x 4 mm 6.0 HEAD
|
2
|
0.00133
|
0.00266
|
||
|
USB
CABLE
|
1
|
4.38000
|
4.38000
|
||
|
BATTERY
SEPARATOR SHEET
|
1
|
0.01079
|
0.01079
|
||
|
GIFT
BOX for CHC
|
1
|
0.29448
|
0.29448
|
||
|
INSTRUCTION
MANUAL (A4, 1C+1C)
|
1
|
0.04131
|
0.04131
|
||
|
TRAY
- BOTTOM for CHC
|
1
|
0.10793
|
0.10793
|
||
|
TRAY
- TOP for CHC
|
1
|
0.10793
|
0.10793
|
||
|
INNER
CARTON for CHC
|
0.1
|
0.32379
|
0.03238
|
||
|
OUTER
CARTON for CHC
|
0.05
|
0.66624
|
0.03331
|
||
|
Total
|
10.21
|
||||
|
Material
Cost with Scarp
|
10.21
|
||||
|
Manufacturing
Cost & Overhead
|
6.19
|
||||
|
Total
Cost in USD FOB HK
|
16.40
|
(Testing
jig and testing time cost not included)
|
|||
|
Remarks:
|
|||||
|
1.
Total cost DOES NOT include OKI IC Cost
|
|||||
|
2.
Total cost INCLUDES USB-Serial Adaptor & Cable Cost @
US$4.38
|
|||||
|
3.
CHC Minimum Order Quantity is 4,000pcs
|
|||||
|
1.
|
MCU
Supplier
|